Contents Vol. 29, 1999

Haemostasis

Fundamental Mechanisms Implicated in Thrombosis: New Aspects
Guest Editors: Lévy-Toledano, S. (Paris); Hemker, H.C. (Maastricht)
15th International Congress on Thrombosis
Antalya, Turkey, October 16–21, 1998

Preface
3 Fundamental Mechanisms Involved in Thrombosis and Haemostasis
Lévy-Toledano, S. (Paris); Hemker, H.C. (Maastricht)

4 Platelet Signal Transduction Pathways: Could We Organize Them into a ‘Hierarchy’?
Lévy-Toledano, S. (Paris)

16 Platelet Collagen Receptors: A New Target for Inhibition?
Clemetson, K.J. (Berne)

27 Regulation of Megakaryocytopoiesis
Caen, J.P. (Paris); Han, Z.C. (Tianjin); Bellucci, S.; Alemany, M. (Paris)

41 Recent Advances in Platelet-Polymorphonuclear Leukocyte Interaction
de Gaetano, G.; Cerletti, C.; Evangelista, V. (Santa Maria Imbaro)

50 On the Coagulation of Platelet-Rich Plasma. Physiological Mechanism and Pharmacological Consequences
Béguin, S.; Keularts, I. (Maastricht)

58 The Haemostatic Balance – Astrup Revisited
Gaffney, J.P.; Edgell, T.A.; Whitton, C.M. (Potters Bar)

72 Author Index Vol. 29, No. 1, 1999

72 Subject Index Vol. 29, No. 1, 1999

Venous and Arterial Thrombosis: Pathophysiologic and Clinical Aspects
Guest Editors: Hemker, H.C. (Maastricht); Lévy-Toledano, S. (Paris)
15th International Congress on Thrombosis
Antalya, Turkey, October 16–21, 1998

Preface
75 Pathophysiologic and Clinical Aspects of Venous and Arterial Thrombosis
Hemker, H.C. (Maastricht); Lévy-Toledano, S. (Paris)

76 Clinical Aspects and Laboratory Problems in Hereditary Thrombophilia
Samama, M.-M.; Gerotziafas, G.; Conard, J.; Horellou, M.-H.; Elalamy, I. (Paris)

100 Antiphospholipid-Thrombosis Syndromes
Bick, R.L.; Arun, B.; Frenkel, E.P. (Dallas, Tex.)

111 Disseminated Intravascular Coagulation. Clinical and Pathophysiologic Mechanisms and Manifestations
Bick, R.L.; Arun, B.; Frenkel, E.P. (Dallas, Tex.)

135 Diagnostic Approach of Phospholipid-Dependent Antibodies. State-of-the-Art Lecture
Amiral, J. (Andresy)

150 Oral Anticoagulant Therapy: Efficacy, Safety and the Low-Dose Controversy
Coccheri, S.; Palareti, G.; Cosmi, B. (Bologna)

166 Statins as Cellular Antithrombotics
Fenton, J.W., II (Albany, N.Y.); Shen, G.X. (Winnipeg)

170 Conjectures and Refutations on the Mode of Action of Heparins. The Limited Importance of Anti-Factor Xa Activity as a Pharmaceutical Mechanism and a Yardstick for Therapy
Béguin, S. (Maastricht); Welzel, D. (Regensburg); Al Dieri, R.; Hemker, H.C. (Maastricht)

179 On the Identification of Beneficial and Detrimental Molecular Forms of Fibrinogen
Henschen-Edman, A.H. (Irvine, Calif.)

187 Author Index Vol. 29, No. 2–3, 1999

188 Subject Index Vol. 29, No. 2–3, 1999
Effects of Clopidogrel on Platelet Activation and Coagulation of Non-Anticoagulated Rat Blood under High Shear Stress

Usefulness of Screening for Congenital or Acquired Hemostatic Abnormalities in Women with Previous Complicated Pregnancies

Biochemical Characterization of a Thrombin Inhibitor from the Bloodsucking Bug Dipetalogaster maximus

Genetic Risk Factors in Acute Coronary Disease

Hemorheological Profile in Chronic Venous Insufficiency after Surgery

Determination of the Prevalence of Fibrinogen Banks Peninsula Mutation (280Tyr-Cys) by PCR

Acquired Bernard-Soulier Syndrome: A Case with Necrotizing Vasculitis and Thrombosis

Protein-Bound Heparin/Heparan Sulfates in Human Adult and Umbilical Cord Plasma

Infusion Phlebitis in Post-Operative Patients: When and Why

Effect of Ticlopidine on Platelet-Derived Microparticles in Patients with Connective Tissue Diseases

Combined Administration of Dextran 70 and Dalteparin Does Not Increase Perioperative Blood Loss Compared to Dextran 70 Alone in Major Orthopedic Surgery

Comparison of the Effects of Acetylsalicylic Acid, Ticlopidine and Cilostazol on Primary Hemostasis Using a Quantitative Bleeding Time Test Apparatus

Soluble P-Selectin and Proinflammatory Cytokines in Patients with Polygenic Type IIa Hypercholesterolemia

Four Cases of Bleeding Diathesis in Children due to Congenital Plasminogen Activator Inhibitor-1 Deficiency

The FVIII Activating Protease Cleaves Single-Chain Plasminogen Activators

Book Review

Contents

Haemostasis Vol. 29, 1999
### Original Papers

<table>
<thead>
<tr>
<th>No.</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>301</td>
<td>Comparative Inhibition of LPS-Activated Human Monocyte-Induced Thrombin Generation by Unfractionated Heparin and Low Molecular Weight Heparins</td>
<td>Nguyên, P.; Rémy, M.-G.; Potron, G. (Reims)</td>
</tr>
<tr>
<td>310</td>
<td>Thromboprophylaxis in Hip Fracture Surgery: A Pilot Study Comparing Danaparoid, Enoxaparin and Dalteparin</td>
<td>The TIFDED Study Group</td>
</tr>
<tr>
<td>326</td>
<td>Differential Behaviour of Coagulation Factor XIII in Patients with Inflammatory Bowel Disease and in Patients with Giant Cell Arteritis</td>
<td>Vrij, A.A. (Maastricht); Rijken, J.; van Wersch, J.W.J. (Heerlen); Stockbrügger, R.W. (Maastricht)</td>
</tr>
<tr>
<td>336</td>
<td>Correlation of Circulating 17ß-Oestradiol with Haemostatic Factors in Healthy Postmenopausal Women</td>
<td>Mukherjee, M.; DeLorenzo, F.; Kazdizola, Z.; Rutila, A.; Ranslall, N.; Sembhi, K.; Dawan, G.; Kıkkar, V.V. (London)</td>
</tr>
</tbody>
</table>

### Suppl. 1

**Thromboembolism: New Achievements and Challenges**
Proceedings 6th International Symposium on Thromboembolic Diseases, Lisbon, June 4–5, 1999
Editors: Haas, S. (Munich); Levine, M. (Hamilton, Ont.); Samama, M.M. (Paris)

<table>
<thead>
<tr>
<th>No.</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>353</td>
<td>Factors Influencing the Length of a Blood Trail</td>
</tr>
<tr>
<td>357</td>
<td>Author Index Vol. 29, 1999</td>
</tr>
<tr>
<td>358</td>
<td>Subject Index Vol. 29, 1999</td>
</tr>
</tbody>
</table>

### Drug Dosage

The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.

**All rights reserved.**

No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center (see 'General Information').

© Copyright 1999/2000 by S. Karger AG, P.O. Box, CH-4009 Basel (Switzerland). Printed in Switzerland on acid-free paper by Reinhardt Druck, Basel.